Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
Elena Castro(Research Institute Hospital 12 de Octubre), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Tokhir Dadaev(Institute of Cancer Research), Julian Adlard(Chapel Allerton Hospital), Antonis C. Antoniou(Weatherford College), Chee Goh(Institute of Cancer Research), Douglas F. Easton(University of Cambridge), Zsofia Kote‐Jarai(Institute of Cancer Research), Marc Tischkowitz(University of Cambridge), Koveela Govindasami(Institute of Cancer Research), Edward J. Saunders(Institute of Cancer Research), Jacqueline Eason(Nottingham University Hospitals NHS Trust), David Olmos(Spanish National Cancer Research Centre), Michael J. Kennedy(University of Virginia), D. Gareth Evans(Manchester Academic Health Science Centre), Malgorzata Tymrakiewicz(Institute of Cancer Research), Trevor Cole(Birmingham Women's Hospital), Alan Donaldson(University Hospitals Bristol NHS Foundation Trust), Mary Porteous(University of Edinburgh), Fiona Douglas(University of Southern California), Michelle Guy(Institute of Cancer Research), Rosemarie Davidson(The Netherlands Cancer Institute), Carole Brewer(Royal Devon and Exeter Hospital), Debra Frost(University of Cambridge), Elizabeth Bancroft(Royal Marsden NHS Foundation Trust), Diana Eccles(Princess Anne Hospital), Daniel Leongamornlert(University of Southern California)
Cited by 374
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k